Answers are grounded in this paper and cite their sources.
Rosmarinic acid (RA) is a natural polyphenolic compound with antioxidant, anti-inflammatory, anti-apoptotic, and neuroprotective activities. However, its potential mechanisms against Alzheimer’s disease (AD) remain incompletely understood. In this study, cross-platform pharmacokinetic evaluation, network pharmacology, molecular docking, and molecular dynamics (MD) simulations were integrated to investigate the potential targets and mechanisms of RA against AD. The ADME-related properties of RA were evaluated using TCMSP, SwissADME, and pkCSM. RA-related targets were collected from SwissTargetPrediction, the Comparative Toxicogenomics Database, and the Similarity Ensemble Approach, whereas AD-related targets were retrieved from GeneCards and the Comparative Toxicogenomics Database. A total of 131 overlapping targets were identified. The protein–protein interaction network contained 130 nodes and 2,455 edges, with TNF, AKT1, IL6, IL1B, CASP3, BCL2, NFKB1, MAPK3, TLR4, and EGFR identified as representative hub targets. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses indicated that these targets were mainly associated with oxidative stress, neuroinflammation, apoptosis, and neuronal survival-related pathways, including the IL-17, TNF, Toll-like receptor, MAPK, NF-κB, PI3K–Akt, apoptosis, and AD pathways. Molecular docking showed favorable binding affinities of RA for AKT1 and CASP3, with binding energies of −7.10 and −6.07 kcal/mol, respectively. The 100-ns MD simulations further supported the conformational stability of both complexes. MM/PBSA analysis yielded binding free energies of −11.96 kcal/mol for RA–AKT1 and −7.82 kcal/mol for RA–CASP3. Cross-platform predictions also indicated limited oral absorption and brain exposure of RA. Overall, RA may exert protective effects against AD through coordinated regulation of oxidative stress-, inflammation-, and apoptosis-related networks, with AKT1 and CASP3 representing candidate binding targets requiring further experimental validation.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: